Processing

Please wait...

Settings

Settings

Goto Application

1. WO2010056194 - 5H-PYRROLO [ 3, 4-B] PYRIDIN DERIVATIVES AND THEIR USE

Publication Number WO/2010/056194
Publication Date 20.05.2010
International Application No. PCT/SE2009/051291
International Filing Date 13.11.2009
IPC
C07D 471/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/4745 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4745condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61P 25/28 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
CPC
A61K 31/4745
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
4738ortho- or peri-condensed with heterocyclic ring systems
4745condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
C07D 471/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
Applicants
  • ASTRAZENECA AB [SE]/[SE] (AllExceptUS)
  • HOLENZ, Jörg [DE]/[SE] (UsOnly)
  • KARLSTRÖM, Sofia [SE]/[SE] (UsOnly)
  • KIHLSTRÖM, Jacob [SE]/[SE] (UsOnly)
  • KOLMODIN, Karin [SE]/[SE] (UsOnly)
  • LINDSTRÖM, Johan [SE]/[SE] (UsOnly)
  • RAKOS, Laszlo [SE]/[SE] (UsOnly)
  • ROTTICCI, Didier [FR]/[SE] (UsOnly)
  • SÖDERMAN, Peter [SE]/[SE] (UsOnly)
  • SUNDSTRÖM, Marie [SE]/[SE] (UsOnly)
  • SWAHN, Britt-Marie [SE]/[SE] (UsOnly)
  • VON BERG, Stefan [DE]/[SE] (UsOnly)
Inventors
  • HOLENZ, Jörg
  • KARLSTRÖM, Sofia
  • KIHLSTRÖM, Jacob
  • KOLMODIN, Karin
  • LINDSTRÖM, Johan
  • RAKOS, Laszlo
  • ROTTICCI, Didier
  • SÖDERMAN, Peter
  • SUNDSTRÖM, Marie
  • SWAHN, Britt-Marie
  • VON BERG, Stefan
Agents
  • ASTRAZENECA INTELLECTUAL PROPERTY
Priority Data
61/114,60814.11.2008US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) 5H-PYRROLO [ 3, 4-B] PYRIDIN DERIVATIVES AND THEIR USE
(FR) DÉRIVÉS DE 5H-PYRROLO [ 3, 4-B] PYRIDINE ET LEUR UTILISATION
Abstract
(EN)
The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.
(FR)
La présente invention concerne de nouveaux composés de formule (I) et leurs compositions pharmaceutiques. De plus, la présente invention concerne des méthodes thérapeutiques destinées au traitement et/ou à la prévention des pathologies liées à la protéine Aβ comme le syndrome de Down, une angiopathie β-amyloïde telle que, mais non exclusivement, l'angiopathie amyloïde cérébrale ou l'hémorragie cérébrale héréditaire, les pathologies associées à un trouble cognitif tel que, mais non exclusivement, un trouble cognitif léger (MCI), la maladie d'Alzheimer, les pertes de mémoire, les symptômes de déficit de l'attention associés à la maladie d'Alzheimer, une neurodégénérescence associée aux maladies telles que la maladie d'Alzheimer ou la démence y compris la démence d'origine dégénérative et vasculaire mixte, la démence pré-sénile, la démence sénile et la démence associée à la maladie de Parkinson, la paralysie supranucléaire progressive, ou la dégénérescence cortico-basale.
Latest bibliographic data on file with the International Bureau